Peptide Library

Human study PLS-00130

Defective in vitro gamma interferon production and elevated serum immunoreactive thymosin beta 4 levels in patients with inflammatory bowel disease.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Defective in vitro gamma interferon production and elevated serum immunoreactive thymosin beta 4 levels in patients with inflammatory bowel disease.primary · Clinical immunology and immunopathology · 1988-04-01 · PMID 3127096 · DOI

Design and participants

Design
Cross-sectional study
Population
Patients with Crohn's disease (21), patients with ulcerative colitis (15), patients with non-IBD gastrointestinal disease as disease controls (12), and healthy controls (28).
Conditions
Crohn's disease, Ulcerative colitis, Inflammatory bowel disease
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
Research Support, Non-U.S. Gov't (per publication type); funder not named

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): The authors conclude that in vitro IFN-gamma production by blood mononuclear cells is defective in IBD and that this appears independent of endocrine thymus regulation. They report serum thymosin beta 4 was elevated in all patient groups.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate endpoint: Thymosin beta 4 was only measured as an endogenous serum level. It was not administered, so no treatment effect can be inferred.
    • abstract only: Only the abstract is available. Methods, assay details and numeric results are not reported in the record.
    • small or imprecise: Small groups (12 to 28 participants each), and no effect sizes or p-values are given in the abstract.
    • other: No thymosin beta 4 was administered. Serum levels were measured as an endogenous marker, so the study cannot inform on treatment effects or safety.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 3127096, abstract (sentence 7) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 3127096, abstract (sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 3127096, abstract (sentence 6) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 3127096, abstract (sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 3127096, abstract (sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).